
December 31, 2021

BSE Limited

Code: 532321

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited

Code: Cadilahc

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated December 31, 2021 titled "**Zydus Cadila receives tentative approval from USFDA for Pimavanserin Capsules**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zy+us Cadila receives tentative approval from USFDA for Pimavanserin Capsules

Ahmedabad, India, 31 December, 2021

Zy+us Cadila's U.S. subsidiary Zy+us Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Pimavanserin Capsules in the strength of 34 mg (USRLD: Nuplazid® Capsules). Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

About Zy+us

Zy+us Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.

**